Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Bioaffinity Technologies WT (BIAFW)

Bioaffinity Technologies WT (BIAFW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors Business Wire - Tue Sep 1, 7:00AM CDT

More than 680,000 Americans living with a history of lung cancer represent a significant population requiring ongoing surveillance Noninvasive CyPath® Lung has the potential...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 Business Wire - Thu Aug 20, 7:00AM CDT

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung Business Wire - Tue Aug 18, 7:00AM CDT

New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide Agreement significantly...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules PR Newswire - Fri Aug 14, 10:45AM CDT

JERSEY CITY, N.J. , Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc....

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules Business Wire - Fri Aug 14, 10:07AM CDT

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules PR Newswire - Thu Aug 13, 9:00AM CDT

JERSEY CITY, N.J.,  , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies,...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules Business Wire - Thu Aug 13, 8:07AM CDT

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung Business Wire - Fri Aug 7, 7:00AM CDT

CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and advances longitudinal clinical...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung Business Wire - Mon Jul 27, 7:08AM CDT

Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway ...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD Business Wire - Wed Jul 22, 7:08AM CDT

Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide ...

BIAF : 6.53 (+43.20%)
BIAFW : 0.1106 (+47.27%)

Barchart Exclusives

1 Cheap Stock Under $10 for Aggressive Investors to Buy on the Dip Barchart - 25 minutes ago
Miniso shares hit a multi-year low after weak Q2 2026 results exposed deteriorating overseas profitability. Despite analyst downgrades, a cheap valuation and a new buyback-focused capital return plan make it a speculative rental play, not a long-term hold. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.